Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11965624 | 1.00 | LMNA (0.41) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL11965627 | 0.81 | LMNA (0.40) | LMNATHRBSMN1; SMN2HIF1ATSHR | |
| SCHEMBL3334720 | 0.81 | LMNA (0.40) | LMNATHRBSMN1; SMN2HIF1ATSHR | |
| SCHEMBL17198380 | 0.79 | TDP1 (0.45) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL6758744 | 0.77 | LMNA (0.36) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL20013779 | 0.76 | LMNA (0.51) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL15279673 | 0.75 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL14950624 | 0.75 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL12928917 | 0.75 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL10350038 | 0.75 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242120-B2 | Carbocyclic compounds and methods for treating emerging disease, including influenza and Venezuela equine encephalitis virus | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100144664-A1 | CARBOCYCLIC COMPOUNDS AND METHODS FOR TREATING EMERGING DISEASE, INCLUDING INFLUENZA AND VENEZUELA EQUINE ENCEPHALITIS VIRUS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (GA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144664-A1 | CARBOCYCLIC COMPOUNDS AND METHODS FOR TREATING EMERGING DISEASE, INCLUDING INFLUENZA AND VENEZUELA EQUINE ENCEPHALITIS VIRUS | HTR3C, APOBEC3C, CUL5 | LMNA 4298/4885THRB 1466/4885SMN1; SMN2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.